The Case of the World Health Organization (WHO)

The World Health Organization (WHO) is the leading intergovernmental organisation in the field of health. WHO fulfils a core public policy objective by providing its Member States an institution devoted to co-operation and co-ordination, including of a regulatory nature, in the field of health. It is particularly active in providing a platform for exchange of information among regulators, pursuing data collection and analysis, putting a strong accent on the importance of research, and having an extensive range of different normative activities. WHO is also involved in crisis management in support of health emergencies faced by its Members States. WHO has undertaken extensive internal reforms to ensure its continued relevance as the United Nations public health arm, which provides a useful reference for other international organisations. This case study provides an overview of WHO’s role in International Regulatory Co-operation (IRC) – its institutional context, its main characteristics, its impacts, successes and challenges.

Contents
The context of the regulatory co-operation
Main characteristics of regulatory co-operation in the context of WHO
Assessment of the impact and success of regulatory co-operation through WHO

www.oecd.org/gov/regulatory-policy/irc.htm
International Regulatory Co-operation and International Organisations

The Case of the World Health Organization (WHO)

By WHO Office of the Legal Counsel

Organisation for Economic Co-operation and Development
World Health Organization
2 November 2016
Foreword

This study was developed in the framework of OECD work on international regulatory co-operation (IRC). It is part of a series started in 2014 that provides detailed overviews of the structure, governance, instruments and processes of international organisations (IOs) in support of international rule-making and standard-setting. To date the series includes the cases of the OECD, the International Maritime Organization (IMO), the Food and Agriculture Organization of the United Nations (FAO), the International Organization for Standardization (ISO), the International Organization of Legal Metrology (OIML), the World Health Organization (WHO) and the UN Economic Commission for Europe (UNECE).

The case studies complement the report on International Regulatory Co-operation: The Role of International Organisations in Fostering Better Rules of Globalisation, which compares the governance modalities and rule-making processes of 50 different IOs in enabling IRC between their Members. They aim to illustrate with greater in-depth and specific evidence the key features, challenges and successes of IOs in setting global rules, and to point out more subtle features of individual organisations that cannot stand out from a broader comparative analysis.

This work is the result of a two-year process that involved discussions on the role of IOs in fostering better rules of globalisation as part of meetings convened annually by the OECD since 2014. It benefitted from the strong commitment of a core group of organisations composed of FAO, IMO, ISO, OECD, OIML, UNECE and WHO established to provide strategic guidance and specific inputs to the project. The work built on a joint methodology and structure to ensure comparability across case studies; and on an innovative partnership between the OECD, the five IOs involved and the Nanterre Centre of International Law (CEDIN).

The OECD prepared the common structure used to develop the studies and organised the technical workshops bringing together the IOs and the CEDIN to guide the structure and substance and discuss the progress made and challenges faced in the research and drafting phases. In addition, the OECD ensured the quality control by reviewing the different drafts of the case studies and managing the circulation of the final draft to OECD delegates and the 50 IOs involved in the work.
A number of CEDIN students, under the direction of Professor Jean-Marc Thouvenin, former Director, contributed closely to the development of the case studies and carried out an internship in the IOs under study to get acquainted to their functioning. The five IOs dedicated staff to work on the case studies, provided access to their processes and information to the students and ensured internal coordination for a comprehensive view of the variety of their practices.

The case study of the World Health Organization was drafted by the Office of the Legal Counsel, with the support of Gian Luca Burci, Adjunct Professor, Graduate Institute of International and Development Studies; Steven Solomon, Principal Legal Officer, WHO Office of the Legal Counsel; Egle Granziera, Legal Officer, WHO Office of the Legal Counsel; Claudia Nannini, Associate Legal Officer, WHO Office of the Legal Counsel; Angelika Tritscher, Coordinator, WHO Risk Assessment and Management; Nathan Ford, Project Manager, WHO HIV Treatment and Care; Susan Norris, Scientist, WHO Research, Ethics and Knowledge Management; Raffaella Balocco, Scientist, WHO Technologies Standards and Norms; Fernando Martin-Gonzalez, Technical Officer, WHO Global Preparedness, Surveillance and Response; Tom Heilandt, Secretary of the Codex Alimentarius Commission; Luis Cousin, Intern, WHO Office of the Legal Counsel.

This work was developed as part of a joint project on the rule-making of international organisations under the leadership of Rolf Alter, Director for Public Governance and Territorial Development and Nicola Bonucci, Director for Legal Affairs. It was co-ordinated by Céline Kauffmann, Deputy Head, under the supervision of Nick Malyshev, Head of the OECD Regulatory Policy Division. The OECD review team in charge of quality and comparability control comprised Caroline Breton and Céline Folsché (Legal Affairs), Marianna Karttunen and Céline Kauffmann (Regulatory Policy Division). The draft benefitted from comments from the OECD Health Division. The case study was prepared for publication by Jennifer Stein.

The work on IRC in international organisations is being conducted under the supervision of the OECD Regulatory Policy Committee, whose mandate is to assist both members and non-members in building and strengthening capacity for regulatory quality and regulatory reform.

The Regulatory Policy Committee is supported by staff within the Regulatory Policy Division of the Public Governance and Territorial Development Directorate. The OECD Public Governance and Territorial Development Directorate’s unique emphasis on institutional design and policy implementation supports mutual learning and diffusion of best
practice in different societal and market conditions. The goal is to help countries build better government systems and implement policies at both national and regional level that lead to sustainable economic and social development. The directorate’s mission is to help governments at all levels design and implement strategic, evidence-based and innovative policies to strengthen public governance, respond effectively to diverse and disruptive economic, social and environmental challenges and deliver on government’s commitments to citizens.
# Table of contents

**Acronyms and abbreviations** ....................................................................................... 9  
**Introduction** ............................................................................................................... 11  
**The context of the regulatory co-operation** .............................................................. 13  
  Area of work and objectives .................................................................................... 13  
  Institutional landscape and WHO’s position in that landscape ............................... 14  
  Reform of the World Health Organization .............................................................. 19  
**Main characteristics of regulatory co-operation in the context of WHO** .......... 21  
  Governance arrangements and operational modalities ............................................ 21  
  Forms of regulatory co-operation provided by WHO to its Member States .......... 26  
  Ensuring the quality of WHO instruments .............................................................. 37  
**Assessment of the impact and success of regulatory co-operation through WHO** ...................................................................................................................... 45  
  Benefits, costs and challenges of regulatory co-operation ..................................... 45  
  Assessment of success ............................................................................................. 46  
**Conclusion** ................................................................................................................. 49  
**Notes** ........................................................................................................................... 51  
**References** .................................................................................................................. 56
# Acronyms and abbreviations

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>APOC</td>
<td>African Programme for Onchocerciasis Control</td>
</tr>
<tr>
<td>BAN</td>
<td>the British Approved Names</td>
</tr>
<tr>
<td>CEDIN</td>
<td>Nanterre Centre of International Law</td>
</tr>
<tr>
<td>COP</td>
<td>Conference of the Parties</td>
</tr>
<tr>
<td>DCF</td>
<td>Dénominations Communes Françaises</td>
</tr>
<tr>
<td>EUAL</td>
<td>Emergency Use Assessment and Listing</td>
</tr>
<tr>
<td>FAO</td>
<td>Food and Agriculture Organization of the United Nations</td>
</tr>
<tr>
<td>GDG</td>
<td>Guideline Development Group</td>
</tr>
<tr>
<td>GISRS</td>
<td>Global influenza surveillance and response system</td>
</tr>
<tr>
<td>GRC</td>
<td>Guidelines Review Committee</td>
</tr>
<tr>
<td>IARC</td>
<td>International Agency for Research on Cancer</td>
</tr>
<tr>
<td>ICDRAs</td>
<td>International Conference of Drug Regulatory Authorities</td>
</tr>
<tr>
<td>IEOAC</td>
<td>Independent Expert Oversight Advisory Committee</td>
</tr>
<tr>
<td>IGO</td>
<td>intergovernmental organisation</td>
</tr>
<tr>
<td>IHR</td>
<td>International Health Regulations (2005)</td>
</tr>
<tr>
<td>IMO</td>
<td>International Maritime Organization</td>
</tr>
<tr>
<td>IMR</td>
<td>Indicator and Measurement Registry</td>
</tr>
<tr>
<td>INFOSAN</td>
<td>International Food Safety Authorities Network</td>
</tr>
<tr>
<td>INN</td>
<td>International Non-proprietary Names Programme</td>
</tr>
<tr>
<td>IOs</td>
<td>International organisations</td>
</tr>
<tr>
<td>IRC</td>
<td>International regulatory co-operation</td>
</tr>
<tr>
<td>ISO</td>
<td>International Organization for Standardization</td>
</tr>
<tr>
<td>JAN</td>
<td>Japanese Adopted Names</td>
</tr>
<tr>
<td>Acronym</td>
<td>Description</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
</tr>
<tr>
<td>NRI</td>
<td>National reporting instrument</td>
</tr>
<tr>
<td>NSAs</td>
<td>Non-State Actors</td>
</tr>
<tr>
<td>OIE</td>
<td>World Organization for Animal Health</td>
</tr>
<tr>
<td>OIML</td>
<td>International Organization of Legal Metrology</td>
</tr>
<tr>
<td>PAHO</td>
<td>Pan American Health Organization</td>
</tr>
<tr>
<td>PBAC</td>
<td>Programme Budget and Administration Committee</td>
</tr>
<tr>
<td>PHEIC</td>
<td>Public health emergency of international concern</td>
</tr>
<tr>
<td>PIP</td>
<td>Pandemic Influenza Preparedness Framework</td>
</tr>
<tr>
<td>PmRN</td>
<td>Paediatric Medicines Regulatory Network</td>
</tr>
<tr>
<td>PPPs</td>
<td>Public-Private Partnerships</td>
</tr>
<tr>
<td>SDGs</td>
<td>Sustainable Development Goals</td>
</tr>
<tr>
<td>SMTA</td>
<td>Standard Material Transfer Agreement</td>
</tr>
<tr>
<td>UNAIDS</td>
<td>United Nations Programme on HIV/AIDS</td>
</tr>
<tr>
<td>UNECE</td>
<td>UN Economic Commission for Europe</td>
</tr>
<tr>
<td>USAN</td>
<td>United States Adopted Names</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>WHO FCTC</td>
<td>WHO Framework Convention on Tobacco Control</td>
</tr>
<tr>
<td>WIPO</td>
<td>World Intellectual Property Organization</td>
</tr>
</tbody>
</table>
Introduction

International co-operation in the field of health started as back as in 1851 when the first international sanitary conference was convened in Paris to harmonise and reduce to a safe minimum the conflicting and costly maritime quarantine requirements of different European nations. This conference led to the adoption of an international sanitary convention, addressing cholera, and was followed by a number of other international and regional arrangements leading to the creation of the World Health Organization (WHO) in 1948.

This case study provides insights into the WHO, a traditional core Intergovernmental organisation (IGO) and specialised agency of the United Nations. WHO, as an institution, reflects the classical approach to treaty-based, centre of government co-operation. WHO fulfils a core public policy objective by providing its Member States an institution devoted to co-operation and co-ordination, including of a regulatory nature, in the field of health. As such, it displays similar features to other IGOs, including a wide variety of different instruments of co-operation, both of a binding and soft law nature.

As a distinct Intergovernmental organisation, however, WHO shows a number of specific features that makes it an interesting case to consider:

- The area of public health includes the involvement of numerous actors, beyond State-actors, including non-governmental organisations, private actors, philanthropic foundations, academic institutions and hybrid institutions such public-private partnerships. Member States of the Organization are committed to effective and extensive collaboration with all these various actors, and at the same time focused on safeguarding the independence and impartiality of the work of the Organization.

- The scientific nature of the issues addressed by the WHO and the high stakes for human health call for extensive exchange of information, data collection, and scientific research, to ensure that health policies are grounded in the best scientific knowledge. This requires a secretariat with highly specialised technical skills.
The threat to human health and safety that some epidemics may present calls for strong resources for emergency action. For this, appropriate means of crisis management are essential for WHO to effectively fulfil its mandate. The WHO has therefore been improving its mechanisms to assist in emergency situations, with the most recent reform in this field introduced in 2016. This presents particularly interesting features within the world of IGOs as sampled in OECD (2016a).

The local and regional nature of certain public health threats calls for means adapted to local specificities and the possibility to act urgently. The six regional offices of WHO, as well as the numerous country offices are a key feature in strengthening the Organization’s ability to collaborate closely with domestic authorities, and through them, local actors and health professionals. This global, regional and national presence, both decentralises WHO activity and, at the same time, ensures alignment at the three levels of the Organization, and constitutes a relatively unique feature of the Organization.

Recently, WHO has undertaken extensive internal reforms to ensure its continued relevance as the United Nations public health arm. This effort is of relevance to other IGOs faced with similar challenges. As part of these efforts, the Organization is working to improve the alignment, flexibility, predictability and transparency of the Organization’s financing, and to improve its risk management activities. In particular, improvements to internal governing practices and to the way the Organization engages with external stakeholders will help clarify and strengthen the position of the Organization and achieve greater coherence among the many players involved in global health.

This case study describes how the Organization supports international regulatory co-operation (IRC) by providing an overview of its institutional context, the main forms of regulatory co-operation it offers to its Member States, and how regulatory quality is safeguarded. It also offers some reflections on the impact and success of regulatory co-operation through WHO.
The context of the regulatory co-operation

Area of work and objectives

The objective of WHO, as defined in Article 1 of its Constitution, is “the attainment by all peoples of the highest possible level of health”. Health is in turn defined positively in the Preamble of the Constitution as “a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity”. The Preamble further provides that “[t]he enjoyment of the highest attainable standard of health is one of the fundamental rights of every human being without distinction of race, religion, political belief, economic or social condition” and “[t]he health of all peoples is fundamental to the attainment of peace and security and is dependent upon the fullest co-operation of individuals and States.”

The Health Assembly, has reaffirmed the right to health, in particular, along the lines of Article I of the Alma Ata Declaration adopted by the International Conference on Primary Health Care in 1978, and has reaffirmed its commitment to the principle enunciated in Article 1 of the Constitution (WHO, 1998).

The scope of the activities of the Organization is ultimately dependent upon its objective – in the sense that, based on the broad definition of WHO’s objective in the Constitution, the Organization has authority to take action in relation to any activity insofar as its effects on health are concerned. The positive and broad definition of “health” enshrined in the Preamble of the Constitution has enabled the Organization to adapt to the “globalisation of public health” (Fidler, 2001). Thus, WHO continues to be able to effectively address new threats to health such as those related to the growing epidemic of noncommunicable diseases, and to interact with other regulatory initiatives in the fields of international security, international trade and intellectual property rights, and the law on access to biological resources.

As the directing and co-ordinating authority on international health work, WHO provides leadership on matters critical to health and engages in partnerships where joint action between countries is needed, helps shape the
research agenda, sets norms and standards, articulates evidence-based policy options, provides technical support to countries and monitors health situation throughout the world. WHO’s work covers a wide range of areas, in particular health systems, noncommunicable and communicable diseases, preparedness, surveillance and response, and the promotion of health through the life course.

Co-operation with domestic authorities is vital to the Organization to ensure follow-up to decisions reached at the international level. WHO works with all Member States to support their national health development process, whether or not WHO has a physical presence in their territories, and co-operates with governments and other partners in supporting countries’ national health strategies and plans.

Six leadership priorities currently give focus and direction to the Organization’s work under a planning tool known as the Twelfth General Programme of Work, 2014-2019. These priorities are:

- advancing universal health coverage;
- accelerating the achievement of the health-related Millennium Development Goals;
- addressing the challenge of noncommunicable diseases and mental health, violence and injuries and disabilities;
- implementing the provisions of the International Health Regulations (2005);
- increasing access to essential, high-quality and affordable medical products; and
- addressing the social, economic and environmental determinants of health.\(^3\)

WHO’s work is further driven by the United Nations Sustainable Development Goals (SDGs), which were adopted by the United Nations General Assembly in September 2015. Health has a central place in SDG 3: Ensure healthy lives and promoting well-being for all at all ages, as well as in the 13 targets relating thereto.

**Institutional landscape and WHO’s position in that landscape**

Although WHO is the specialised agency for global health within the United Nations system, the institutional landscape in which international health co-operation takes place has become increasingly complex. Specific health-related matters also fall under the mandate of other international and
regional IGOs, including the Food and Agriculture Organization of the United Nations (FAO), the World Trade Organization (WTO), the World Organization for Animal Health (OIE) and the World Intellectual Property Organization (WIPO). WHO has a variety of collaboration practices with these organisations, and with other specialised UN agencies, as well as regional and intergovernmental organisations. Modes of interaction span a broad range of instruments, including co-sponsored programmes, MoUs, joint meetings and exchange of information (OECD, 2016). Furthermore, WHO interacts with a broad range of other bodies operating in the field of health, such as partnerships and non-State actors (NSAs).

**United Nations and other intergovernmental organisations**

Co-operation with the United Nations and other IGOs is explicitly foreseen in the Constitution and is conducted on the basis of multilateral and bilateral agreements and arrangements. In addition, WHO closely interacts with the United Nations system through various decision making organs including the Chief Executives Board, the United Nations Development Group, the High Level Committee on Management and the High Level Committee on Programmes. The Head of a WHO Country Office is a member of the United Nations Country Team co-ordinated by the United Nations Resident Coordinator, and WHO offices actively engage in the development and implementation of the United Nations Development Framework.

Co-operation with IGOs is also explicitly foreseen in the WHO International Health Regulations (2005) (IHR) and the WHO Framework Convention on Tobacco Control (WHO FCTC), which will be presented later in the chapter. Under the IHR, WHO is expected to co-operate and co-ordinate its activities with other competent IGOs or international bodies in the implementation of the Regulations, including through the conclusion of agreements or similar arrangements. Under the WHO FCTC, the Conference of the Parties may request the co-operation of competent international and regional IGOs, including financial and development institutions. Also, there are many instruments such as resolutions and decisions adopted by the Health Assembly that call on partners, including IGOs, to support and contribute to the accomplishment of the instrument concerned, and to work jointly with Member States and with the WHO Secretariat, as appropriate. In many cases, and in accordance with the mandate received by the governing bodies, UN agencies and other competent IGOs participate in the development process of such policies by providing, along with Member States and other interested stakeholders, comments on preparatory work towards such instruments.
The WHO may also collaborate on specific time-bound projects with other IGOs, for instance through the establishment of a joint commission. This was the case regarding the UN High-level Commission on Health Employment and Economic Growth, a one year collaboration with the OECD and the ILO, tasked with proposing actions to stimulate the creation of health and social sector jobs as a means to advance inclusive economic growth, paying specific attention to the needs of low- and lower middle income countries.

Additionally, the WHO Secretariat arranges more informal working processes and participates jointly with other IGOs in activities, in furtherance of its mandates. Mention can be made, for instance, of WHO’s participation in the Joint Emergency Management Plan of the International Organizations, effective as of 1 July 2013, which describes the framework for preparedness for and response to an actual, potential or perceived radiation incident or emergency and, specifically, the arrangements of the participating international organisations for responding to any such incident or emergency. Co-operation with regional IOs, such as the European Union and the African Union, has also become particularly important at all three levels of the organisation, i.e. at the global, regional and country level.

Cosponsored programmes also provide an interesting example of effective co-operation of WHO with other IGOs. Cosponsored programmes are integral to core WHO activities and part of its programmatic accountability framework, but are financially and/or programmatically cosponsored by a number of other agencies. Cosponsored programmes include the Special Programme on Research and Training in Tropical Diseases (TDR), the Special Programme of Research, Development Research and Training in Human Reproduction (HRP), the African Programme for Onchocerciasis Control (APOC), and the FAO/WHO Joint Food Standards Programme (Box 1 and OECD 2016b). The United Nations Programme on HIV/AIDS (UNAIDS), established in 1995, is also cosponsored by WHO and several other UN agencies, programmes and funds. UNAIDS is located in Geneva and has its own governance structure, which comprises the Programme Coordinating Board, the Committee of Cosponsoring Organizations and the Secretariat.
Box 1. The Joint FAO/WHO Food Standards Programme (Codex Alimentarius)

The Joint FAO/WHO Food Standards Programme (Codex Alimentarius) was established by the governing bodies of FAO and WHO in 1961 and 1963 respectively. Since its inception, the joint programme has produced a large amount of food standards, which are collected in the Codex Alimentarius.

The principal organ of the Codex Alimentarius is the Codex Alimentarius Commission, which adopts food standards and provides for their publication. The Commission is also empowered to establish subsidiary bodies such as General Subject Committees, which develop science-based concepts and principles applying to foods in general, specific foods or groups of foods; and Commodity Committees, which develop standards for specific foods or classes of food.

As a standard-setting programme, co-operation through Codex Alimentarius occurs predominantly through general subject and commodity committees. In addition, standards development concerning commodities traded regionally is organised around regional co-ordination committees in the six Codex geographical regions with biannual meetings and co-ordinators appointed by the Commission for each of the region. There is much interaction between the Member States through these committees, for the development and adoption of these standards and priority settings.

Development and adoption of food standards to be included in the Codex Alimentarius follows a procedure that involves the preparation and discussion of a project proposal at committee level, the review of such proposal by the executive organ of the Commission, the preparation of a draft text and its circulation to Members and interested parties for comments, finalisation of the draft and, eventually, its adoption by the Commission as a formal Codex text, which is then published by the Secretariat.

Codex standards may concern areas where other international organisations undertake work, such as in the area of fruit and vegetable quality, or food technology standards. This concurrence of competence is often addressed through mutual collaboration, for example by participating as observers in their respective governing bodies.

Although such standards are not per se legally binding, they are widely observed. Most importantly, the WTO Agreement on the Application of Sanitary and Phytosanitary Measures (SPS Agreement) acknowledges the importance of international standards to minimise or eliminate the risk of sanitary, phytosanitary and other technical standards becoming barriers to trade, and specifically identifies the Codex Alimentarius Commission as a relevant standard-setting organisation in this regard.

Importantly, reference to Codex standards in the WTO agreement results in stronger normative status for adoption of Codex standards with respect to States parties to the SPS agreement.

1. See Preamble of the SPS Agreement.
2. Article 3.4 SPS Agreement.
Partnerships, non-State actors, collaborating centres and other international bodies

Issues pertaining to international health involve a wide range of other actors, beyond IGOs. The description of the institutional landscape in which WHO operates would not be complete without mentioning, first of all, public-private partnerships (PPPs), which pursue public health objectives convergent with and complementary to those of WHO. Some PPPs are legally incorporated entities external to WHO, whereas others are unincorporated alliances within WHO with their own governance.

WHO-hosted partnerships derive their legal personality from WHO and are subject to the Organization’s rules and regulations. They have a formal governance structure and programmatic accountability frameworks. WHO currently hosts four PPPs – the International Drug Purchase Facility (UNITAID), the Alliance for Health Policy and Systems Research, the European Observatory on Health Systems and Policies, and the Partnership for Maternal, Newborn and Child Health. As of the time of writing, WHO is represented on the Boards of UNITAID, the Alliance for Health Policy and Systems Research and the Partnership for Maternal, Newborn and Child Health, while the WHO Regional Office for Europe is one of the partners of the European Observatory on Health Systems and Policies.

The Health Assembly has adopted a policy on WHO’s engagement with global health partnerships, which provides a framework to guide WHO’s assessment of, and decisions concerning potential engagement in health partnerships, as well as specific parameters to be applied in cases where WHO agrees to host a formal partnership.

The recently adopted Framework of Engagement with non-State Actors (see below) also applies to the activities of hosted partnerships, as well as to WHO’s engagement in partnerships, including PPPs. For WHO to engage, the partnership must demonstrate a clear added value for public health, have a clear goal that concerns a priority area of work of WHO, be guided by the technical norms and standards of WHO, support national development objectives, ensure appropriate and adequate participation of stakeholders, establish clear roles for partners, and pursue first and foremost public-health goal tasks. In addition, WHO must evaluate transaction costs along with potential benefits and risks, at all levels.

The WHO engages with NSAs due to the significant role they play in the advancement and promotion of public health. While relations with NGOs and commercial enterprises were governed by separate, dedicated policies until May 2016, all WHO’s engagements with NSAs are now governed by a single “Framework of Engagement with non-State Actors”
and its four Policies and Operational procedures related to, respectively, nongovernmental organisations, the private sector, philanthropic foundations and academic institutions.\(^7\)

The Framework is aimed at both promoting engagement and safeguarding the integrity of WHO’s public health mandate.\(^8\) It identifies four types of interaction with NSAs: participation of NSAs in consultations, hearings, and other meetings of the Organization; provision of financial or in-kind contributions; provision of up-to-date information and knowledge on technical issues; advocacy activities; and technical collaboration, including through product development, capacity-building, operational collaboration in emergencies and contribution to the implementation of WHO’s policies. It establishes mechanisms to manage conflicts of interest and other risks of engagement. The Framework will help shape co-operation for future engagements, especially in the normative arena.

In addition, the Organization relies on the expertise provided by approximately 800 formal WHO Collaborating Centres, which carry out activities in support of the Organization’s programme. The regulatory framework surrounding this technical/scientific collaboration is provided by the Regulations for Study and Scientific Groups, Collaborating Institutions and other Mechanisms.\(^9\) Other collaborative efforts, differently named, are in place. For example, WHO provides technical leadership and secretariat support to the Global Alliance Against Chronic Respiratory Diseases, a voluntary alliance of national and international organisations, institutions, and agencies committed towards the common goal to reduce the global burden of respiratory diseases that was launched in 2008. These collaborative arrangements are fully within the scope of WHO policy and managerial control, and subject to WHO governing body oversight.

**Reform of the World Health Organization**

Since 2010, WHO’s capability to handle the increasingly complex challenges in the field of health in the 21st century has been at the heart of a set of reforms discussed by Member States under the leadership of Director-General Dr Margaret Chan.

These reforms encompass three components: programs and priority setting, governance and management. Programmatic reform involves priority setting and a strengthened technical delivery model.\(^10\) On one hand, priorities must be defined and addressed in a systematic, transparent and focused manner; on the other hand, aligning resources – both technical and financial – is essential to the effective and efficient delivery of these priorities and to avoid an overcommitted and overstretched organisation. Steps were taken with the Programme Budget 2014-15 and further
developed in the Programme Budget 2016-17 to have programmatic priorities with clear outputs and supported by adequate financing. The results chain for the Programme budget 2016-17 has also been strengthened by developing indicators for organisational outputs, linked to measurable health outcomes.

Governance reform seeks to clarify and strengthen the positioning of the Organization in an effort to achieve greater coherence among the many players involved in global health. This can be achieved by improving governing practices internally and engaging more effectively with external stakeholders.

Managerial reform seeks to improve WHO’s ability to achieve the best possible results, by attracting and retaining the best talent and using the resources entrusted to the Organization in a more effective and efficient manner. To this end, different human resources reforms, based on the human resources strategy, have been adopted to ensure that staffing is matched to needs at all three levels of the Organization. Other steps have been taken to strengthen accountability, transparency and internal controls, as well as to achieve better evaluation, information management and communication.

Starting with the Special session of the Executive Board in January 2015 following the Ebola outbreak and continuing with the Sixty-ninth World Health Assembly in May 2016, WHO Member States furthermore agreed to support a remarkable innovation in the Organization’s history, the establishment of the new Health Emergencies Programme. The new programme “represents a fundamental development for the Organization, complementing WHO’s traditional technical and normative role with new operational capacities and capabilities for its work in outbreaks and humanitarian emergencies” and “is designed to bring speed and predictability to WHO’s emergency work, using an all hazards approach, promoting collective action, and encompassing preparedness, readiness, response and early recovery activities.” (WHO, 2016c).
Main characteristics of regulatory co-operation in the context of WHO

Governance arrangements and operational modalities

The following sections describe the governance structure of the Organization, its membership, decision-making process and budget. WHO’s near universal membership makes it a global forum for IRC in the field of health. Indeed, normative activities are at the heart of WHO’s functions. Full-financing of the biennial programme budget, which is today mainly achieved through voluntary contributions of Member States and other donors, remains one of the major challenges faced by the Organization.

Membership

WHO is an IGO whose membership is “open to all States” pursuant to Article 3 of its Constitution. States already members of the United Nations may become Members of the WHO by signing or otherwise accepting its Constitution in accordance with their constitutional processes. Other countries may become Members when their application has been approved by a simple majority vote of the Health Assembly. The admission procedure is regulated in more detail in the Rules of Procedure of the Health Assembly. As of 2015, WHO is composed of 194 Member States.

The Constitution provides for an additional category of membership by allowing territories or groups of territories, which are not responsible for the conduct of their international relations, to be admitted as Associate Members upon application made on their behalf by the Member or other authority responsible for their international relations. The rationale behind this provision was the need to ensure participation of such territories in the new Organization. The nature and extent of the rights and obligations of Associate Members have been determined by the Health Assembly. They fully participate in the activities of the Organization, but do not enjoy the right to vote. There are currently only two Associate Members, i.e. Puerto Rico and Tokelau.

Territories or groups of territories, which are not responsible for the conduct of their international relations and which are not Associate Members, have nevertheless the right to be represented and to participate in
regional committees, without the right to vote, upon consultations between the members in the region concerned and the authority having responsibility for their international relations.

**Governance structure**

At the global level the Organization is composed of three organs: the Health Assembly, the Executive Board, and the Secretariat.

*The Health Assembly*

The Health Assembly is the decision-making body of the Organization. It is attended by no more than three delegates per Member, chosen from among the persons most qualified in the field of health, and by as many alternates and advisers as they wish, as well as by representatives of Associate Members and the Executive Board. The Health Assembly meets at least once a year in regular session, and in such special sessions as may be necessary. So far, a special session of the Health Assembly has been convened only once, in 2006, to accelerate the procedure to elect the next Director-General following the death of the former Director-General, Dr Lee Jong-wook.

The functions of the Health Assembly are, *inter alia*, to determine the policies of the Organization, appoint the Director-General, supervise the financial policies of the Organization, review and approve the budget. The main committees of the Health Assembly are Committee A, which deals predominantly with program and budget matters, and Committee B, which deals predominantly with administrative, financial and legal matters.

*The Executive Board*

The Executive Board consists of 34 persons, technically qualified in the field of health, designated by as many Members for a three-year term. Member States entitled to designate persons to serve on the Executive Board are elected by the Health Assembly, one third of the Executive Board being renewed each year. The Executive Board meets at least twice a year, normally in January and in May right after the Health Assembly’s session, and in such special sessions as may be necessary. So far, three special sessions have been convened, in 2006, 2011 and 2015 respectively, to address: the consequences of the sudden death of the former Director-General, Dr Lee Jong-wook, WHO reform, and the Ebola emergency.

The main function of the Executive Board is to give effect to the decisions and policies of the Health Assembly and to act as the executive organ of the Health Assembly. Among its other functions, the Executive
Board submits a general program of work to the Health Assembly for consideration and approval, establishes such committees as the Health Assembly directs and may, on its own initiative or on the proposal of the Director-General, set up any other committees that will facilitate its work. At present, the Executive Board has established the Programme Budget and Administration Committee (PBAC), which, according to its terms of reference, either makes recommendations to the Executive Board or acts on its behalf; the Independent Expert Oversight Advisory Committee (IEOAC), which reports to the PBAC; and the Standing Committee on Nongovernmental Organisations, which has however been recently abolished further to the adoption of the Framework of Engagement with non-State actors mentioned above.

Representatives of the United Nations and of other participating IGOs, as well as nongovernmental organisations, international business associations and philanthropic foundations which have been granted official relations by the Executive Board in accordance with the Framework of Engagement with non-State actors are invited to participate in sessions of the WHO’s governing bodies.

Furthermore, although the concept of “observers” is not mentioned as such in the WHO Constitution, five “quasi-permanent observers (the Holy See, the Order of Malta, the International Committee of the Red Cross, the International Federation of Red Cross and Red Crescent Societies, and Palestine) are regularly invited to attend sessions of the Health Assembly, in addition to other entities participating based on an ad hoc invitation by the Director-General. Observers may attend, without the right to vote and make a statement on the subject under discussion, upon the invitation of the President or Chairmen of these bodies.

The Secretariat

The Secretariat comprises the Director-General as well as all technical and administrative staff. The Director-General, subject to the authority of the Executive Board, is the chief technical and administrative officer of the Organization and is appointed by the Health Assembly on the nomination of the Executive Board. Staff members are appointed by the Director-General in accordance with the Staff Regulations established by the Health Assembly. As of December 2015, the Organization counted more than 7,000 health and other experts, and support staff, working at all three levels of the Organization.

WHO’s headquarters are located in Geneva, Switzerland, pursuant to a decision by the First World Health Assembly in 1948. However, WHO is, as noted above, characterised by a decentralised nature, key for enabling a
tailored assistance to their Members and fostering exchanges directly between country authorities. Further to a decision of the First World Health Assembly, six geographical areas – Africa, the Americas, South-east Asia, Europe, Eastern Mediterranean and Western Pacific – were defined and six regional organisations set up to meet the special needs of such areas.16

Each regional organisation consists of a regional committee and a regional office led by a regional director. Regional committees are composed of representatives of Member States, Associate Members and other territories, if applicable, in the region concerned. They usually meet once a year. Each regional committee has adopted its own set of procedural rules. Under Article 50 of the Constitution, regional committees are mandated, inter alia, to formulate policies on matters of an exclusively regional character and supervise the activities of the regional office. Regional offices serve as the administrative organs of regional committees and carry out within the region the decisions of the Health Assembly and the Executive Board. They are headed by a Regional Director, appointed by the Executive Board after nomination by the regional committee.

A particular status is enjoyed by the Pan American Health Organization (PAHO) in as much as, under the WHO Constitution, PAHO “shall in due course be integrated with the Organization”. Accordingly, the Directing Council and the Pan American Sanitary Bureau serve respectively as the Regional Committee and the Regional Office of the WHO Region for the Americas based on an agreement between WHO and PAHO.

In addition to regional offices, WHO has also established offices in more than 150 countries, territories and areas, although some WHO country offices provide support to more than one country, territory or area. A WHO office works with the host Ministry of Health, other ministries and government institutions as appropriate. In general, an agreement is concluded between WHO and the government concerned to set out the administrative and legal framework for the technical co-operation between the parties. Each office has a unique profile of staff, programmatic priorities, and finances, which define its modalities of co-operation with a respective Member State and with the wider range of partners active in that country.

WHO’s country offices play a key role in ensuring appropriate technical co-operation with countries and leadership in the health sector. WHO staff located in country offices provide advice on technical issues and provide assistance throughout the health sector. Country office staff help plan, implement and monitor programmes in co-operation with other actors in the region, and support advocacy and resource mobilisation efforts. Finally, the local offices contribute greatly to improve the co-operation between WHO Members. They facilitate exchanges among countries and help builds
capacities, enabling exchanges to be driven primarily by countries themselves (WHO, 2016b). As a specialised agency of the United Nations, led by technical considerations, WHO’s impartiality is a critical factor that greatly contributes to the achievement of health-related objectives.

A number of offices, other than country offices, have been set up to serve as liaison offices (such as the WHO Office at the European Union based in Brussels, Belgium), to provide administrative support (such as the Global Service Centre based in Kuala Lumpur, Malaysia) or to provide technical support on specific health areas (such as the WHO Centre for Health Development based in Kobe, Japan). In addition, geographically dispersed offices have been established within the WHO European Region, which are fully integrated into the work of the Regional Office and provide technical capacity in specific health areas.

**Decision-making process**

Decision-making is formally governed by the principle of “one state, one vote”. The Rules of Procedure of the Health Assembly and the Executive Board provide for decision-making by simple majority except for decision on important questions, such as the adoption of conventions or agreements, amendments to the Constitution, and suspension of the voting privileges and services of Members, for which a two thirds majority of the Members present and voting is required. However, virtually all negotiations are conducted, and almost all decisions are adopted by consensus, which in WHO’s practice is understood as the adoption of decisions without a formal vote but not necessarily as unanimity. Some technical documents prepared by the Secretariat are not subject to member state negotiation or approval.

**Programme and budget**

While WHO’s core functions that guide the work of the Secretariat are established in the General Programme of Work, the programme budget identifies the scope of activities and specifies achievements expected during each two-year period. The regular budget is subject to monitoring and oversight by the governing bodies. The Director-General prepares and submits to the Executive Board the financial statements and budget estimates. The Executive Board has the task of considering the budget estimates and submitting them to the Health Assembly with recommendations it may deem advisable. Then, the Health Assembly reviews and approves the programme budget.

The latest programme budget approved as of the time of writing was USD 4 385 million for the biennium 2016-17, which represented an increase of 8% in “base” budget over the biennium 2014-15. WHO’s financing has
undergone a major transformation over the past decades. WHO is financed through a regular budget funded from contributions assessed on Member States based on the latest available United Nations scale of assessment with a maximum assessment rate of 22% and a minimum assessment rate of 0.001%, taking into account differences in membership between WHO and the United Nations.22

However, the proportion of voluntary contributions has increased significantly to almost three quarters of the Organization’s financing in the last years. Besides Member States, a wide range of donors contributes to WHO activities, for example public agencies or NGOs. In-kind or in-service contributions are accepted after assessment on a case-by-case basis. Starting from 2013, the Health Assembly has approved the budget for biennial financial periods under all sources of funds, namely, assessed and voluntary contributions, instead of assessed contributions only. To ensure that full funding of the Programme Budget can be achieved, a Financing Dialogue has been arranged with Member States and key non-State contributors to ensure that WHO is well-equipped to address the increasingly complex challenges of the health of populations in the 21st century. The financing dialogue process consists of an integrated series of events and activities that includes a strategic planning and preparation phase, two milestone financing dialogue meetings, bilateral meetings, mission briefings and Regional Committee discussions. It aims at improving alignment, transparency, predictability and flexibility of WHO’s financing and broadening WHO’s contributor base.23

**Forms of regulatory co-operation provided by WHO to its Member States**

IRC takes place within WHO in various forms. Very much like other IGOs, the Organization is particularly active in the upstream phases of the policy cycle, providing a platform for exchange of information among regulators, pursuing data collection and analysis, putting a strong accent on the importance of research, and having an extensive range of different standard-setting activities (OECD, 2016). While it is less active in the downstream phase of the policy cycle, WHO still performs crisis management in support of health emergencies faced by its Members States.

**Data collection**

Data collection as well as the production and dissemination of health statistics are a core activity of the Organization. WHO programmes compile and disseminate a broad range of statistics that play a key role in advocacy
for health issues, monitoring and evaluation of health programmes and provision of technical assistance to countries.

Data collection takes place in various ways. At the global level, the Organization provides data and analysis on global health priorities through the Global Health Observatory data repository, which provides access to over 1,000 indicators on priority health topics. The repository contains an extensive list of indicators that can be selected by theme, indicator and country. It issues analytical reports on the current situation and trends for health priority issues.

Publications include the “World Health Statistics”, which compiles statistics for key health indicators on an annual basis, and the “WHO Global Health Estimates” which provides a comprehensive and comparable assessment of mortality and loss of health due to diseases and injuries for all regions of the world. The WHO Indicator and Measurement Registry (IMR) is a central source of metadata of health-related indicators used by WHO and other organisations, which facilitates complete and well-structured indicator metadata, harmonisation and management of indicator definitions and code lists, internet access to indicator definitions, and consistency with other statistical domains.

**Research**

The fundamental importance of research in the field of health as the foundation for sound health policies is recognised in Article 2 of the WHO Constitution. Since its inception, the Organization has opted not to engage directly in primary research, and has instead provided support in the areas of capacity-building, research priorities setting, and standard development for good research practice and affordable health technologies and evidence-informed policy.

The 2010 WHO Strategy on Research for Health is based on the premise that policies and practices in support of health worldwide should be grounded in the best scientific knowledge. A Research Ethics Review Committee (ERC) composed of experts nominated and appointed by the Director-General has been tasked to ensure that research involving human subjects, supported by WHO, meets the highest ethical standards. ERC, which is guided in its work by the World Medical Association Declaration of Helsinki as well as the International Ethical Guidelines for Biomedical Research Involving Human Subjects, is mandated to review all research projects that involve human participants and are supported, either financially or technically, by WHO.
The Organization has several particularly important research-focused initiatives. Special mention should be made of the WHO Centre for Health Development (Kobe Centre), whose focus is on the consequences of social, economic and environmental change and its implications for health policies. The co-sponsored Special Programme for Research and Training in Tropical Diseases supports innovative research on neglected priority needs for disease control whereas the cosponsored Special Programme of Research, Development and Research Training in Human Reproduction is the main instrument within the United Nations system for research in human reproduction. A separate institution for research in cancer – the International Agency on Research in Cancer – was established by the Health Assembly in 1965 (Box 2).

Box 2. The International Agency for Research on Cancer (IARC)

The IARC was created in 1965, through a resolution of the World Health Assembly, as the specialised cancer agency of the World Health Organization. Its objective is to promote international collaboration in cancer research by bringing together a wide range of inter-disciplinary skills. By pursuing its mission, the IARC plays an important role in terms of normative regulatory co-operation. Since 1971, more than 900 environmental factors that can increase the risk of human cancer have been evaluated through the IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Interdisciplinary Working Groups of expert scientists review the published studies and evaluate the weight of the evidence. The Monographs series are complemented by the IARC Handbooks of Cancer Prevention, which provide evaluations of the cancer-preventive potential of agents and interventions and are also produced by an international Working Group of experts. Mention should also be made of the WHO/IARC Classification of Tumours series – authoritative and concise reference books for the histological and molecular classification of tumours prepared by a group of internally recognised experts – as well as of the Scientific and Technical Publications that disseminate the results of IARC-co-ordinated scientific research and focus on particular topics of a technical nature.

WHO significantly avails itself of the expertise and research made available by countries or other partners with WHO playing an important co-ordinating role and validating the outcome of such research (Burci and Vignes, 2004). As mentioned in the first section, several Collaborating Centres, i.e. institutions such as research institutes at national level, parts of universities or academies, have been designated by the Director-General to carry out activities in support of the Organization’s programmes. At the time of writing there are over 700 WHO collaborating centres in over 80 Member States working with WHO on areas such as nursing, occupational health,
communicable diseases, nutrition, mental health, chronic diseases and health
technologies. Networks of collaborating centres have been created in many
technical areas, such as the Global Network of WHO Collaborating Centres
working on Communicable Diseases, the network of WHO Collaborating
Centres for Injury and Violence Prevention and the network of WHO
Collaborating Centres for Traditional Medicine.

Normative functions

Under Article 2 of the Constitution, the Organization can propose
conventions, agreements and regulations, and make recommendations with
respect to international health matters. Although an analysis of the WHO
Constitution and its preparatory work shows that conventions and
agreements were considered as central instruments in the handling of global
health issues, “soft law” in the form of non-binding recommendations has so
far played a much more prominent role (Burci and Vignes, 2004).

Conventions and agreements

The Health Assembly has the authority to adopt conventions and
agreements with respect to any matter within the competence of the
Organization. The Health Assembly has adopted only one international
convention so far, i.e. the WHO Framework Convention on Tobacco
Control (WHO FCTC). Furthermore, in 2012, the Conference of the Parties
to the WHO FCTC adopted the Protocol to Eliminate Illicit Trade in
Tobacco Products, which is open for ratification and accession by Parties to
the Convention. Article 19 of the Constitution requires the majority of
two-thirds of the vote of the Health Assembly to adopt a convention or
agreement, which shall come into force for each Member State when
accepted by it in accordance with its constitutional processes. Article 20 of
the Constitution further prescribes that each Member State will take action
regarding the acceptance of such convention or agreement within eighteen
months after the adoption by the Health Assembly by notifying the Director-
General of the action taken. If it does not accept such convention or
agreement within the time limit, it will furnish a statement of the reasons for
non-acceptance. In case of acceptance, each Member agrees to make an
annual report to the Director-General on the action taken with respect to
such convention or agreement. It should be noted, however, that this
provision has not been rigorously implemented with regard to the WHO
FCTC.
Regulations

Regulations constitute a legally binding yet separate instrument at the disposal of WHO Member States. Article 21 of the WHO Constitution gives the Health Assembly the authority to adopt regulations in five articulated areas, namely i) sanitary and quarantine requirements and other procedures designed to prevent the international spread of disease; ii) nomenclatures with respect to diseases, causes of death and public health practices; iii) standards with respect to diagnostic procedures for international use; iv) standards with respect to the safety, purity and potency of biological, pharmaceutical and similar products moving in international commerce; and v) advertising and labelling of biological, pharmaceutical and similar products moving in international commerce.

This provision is especially innovative because it allows the Organization to provide a particularly efficient process of entry into force – binding all Member States at the same time except for those that may choose to “opt-out”. So far, the Health Assembly has adopted two sets of international regulations under Article 21 of the Constitution.

First, a set of regulations regarding nomenclature with respect to diseases and causes of death were adopted in 1948 and then completely revised in 1967. The 1967 Nomenclature Regulations require Member States to compile mortality and morbidity statistics using the revision in force at any given time of the International Classification of Diseases (ICD).

Second, the Health Assembly has adopted international regulations in the area of sanitary and quarantine requirements and other procedures designed to prevent the international spread of disease. The first set of International Sanitary Regulations were adopted in 1951 and then replaced by and renamed the International Health Regulations in 1969, which were in turn revised in 1973 and 1981. These regulations were intended to monitor and control six specific infectious diseases (cholera, plague, yellow fever, smallpox, relapsing fever and typhus).

To address the growing number of public health risks resulting from increased travel and trade in the last quarter of the 20th century, the Health Assembly at its Fifty-eighth session in 2005 dispensed with a disease-specific model and adopted the revised International Health Regulations (2005), aimed at disease, regardless of source, which entered into force on 15 June 2007 (Box 3).
Box 3. The International Health Regulations (2005) (IHR)

The International Health Regulations (IHR) are an international legal instrument that is binding on 196 countries across the globe, including all the Member States of WHO. Their aim is to prevent, protect against, control and respond to the international spread of disease while avoiding unnecessary interference with international traffic and trade. They are also designed to reduce the risk of disease spread at international airports, ports and ground crossings.

The IHR set an extensive legal framework to ensure exchange of information between countries on public health emergencies, with the WHO centralising the information and thus facilitating access to it. They indeed require countries to notify WHO of all events that may constitute a “public health emergency of international concern” (PHEIC), and to respond to requests for verification of information regarding such events. Countries also have the obligation to report to WHO, as far as practicable, evidence of a public health risk identified outside of their territory which may cause international disease spread, as manifested by exported or imported human cases, vectors which carry infection or contamination, or goods that are contaminated.

States parties to the IHR have delegated to the Director-General the authority to determine whether an event constitutes a PHEIC in accordance with the criteria and procedure set out in the Regulations. In arriving at this determination, the Director-General takes into account several elements, including the advice of an Emergency Committee composed of experts.

WHO’s response to a PHEIC includes temporary recommendations concerning appropriate public health responses for application by the countries affected by such an emergency, as well as by other States and by operators of international transport. Standing recommendations indicating the appropriate measures for routine application for specific ongoing public health risks may also be issued.

Soft law instruments

So far, the Organization has mainly exercised its normative function through the adoption of recommendations by the Health Assembly, styled as “resolutions” or sometimes as “decisions”, as well the development of a diverse range of technical standards by the Secretariat. Article 23 of the Constitution indeed gives power to the Health Assembly to make recommendations with respect to any matter within the competence of the Organization. Irrespective of the many names that can be assigned to them (e.g. codes, strategies, global plans of action, road maps or frameworks), such recommendations are not legally binding upon States. However, they represent the agreed outcome of extensive governing body consideration, and consultation processes with Member States and often other stakeholders involving face-to-face meetings.
Since 1948 the Health Assembly has adopted a large number of these recommendations on a wide range of topics. Mention can be made, for example, of the recently adopted “Global Strategy and Action Plan on Ageing and Health 2016-2020” and the “WHO global plan of action to strengthen the role of the health system within a national multisectoral response to address interpersonal violence, in particular against women and girls, and against children” as well as of the Pandemic Influenza Preparedness Framework (Box 4).

**Box 4. The Pandemic Influenza Preparedness Framework (PIP Framework)**

The PIP Framework is an innovative public health instrument, adopted by the Health Assembly in 2011 in accordance with Article 23 of the Constitution that seeks to better prepare the world to respond to pandemic influenza. It aims at improving pandemic influenza preparedness and response, and strengthening the protection against the pandemic influenza by improving and strengthening the WHO global influenza surveillance and response system (“WHO GISRS”), with the objective of a fair, transparent, equitable, efficient, effective system for, on an equal footing, the sharing of H5N1 and other influenza viruses with human pandemic potential, and access to vaccines and sharing of other benefits.

Under the PIP Framework, the sharing of PIP biological materials within the WHO GISRS network of laboratories is governed by Standard Material Transfer Agreement 1 (SMTA1), which establishes the rights and obligations of GISRS laboratories with respect to many matters. In addition, the Framework establishes two mechanisms to facilitate access to the benefits that result from the sharing of viruses with human pandemic potential: the Partnership Contribution, which is an annual contribution to WHO from influenza vaccine, pharmaceutical and diagnostic manufacturers that use the WHO GISRS; and a Standard Material Transfer Agreement 2 (SMTA 2), which is a legally binding agreement between WHO and non-GISRS entities (including manufacturers, biotechnology firms, and academic and research institutions) that receive PIP biological materials from WHO GISRS.

Of note is also the co-ordination role played by WHO with regard to the sharing of influenza viruses through WHO GISRS. This network has been collecting and monitoring influenza viruses for more than 60 years. WHO GISRS monitors the evolution of influenza viruses and provides recommendations in areas including laboratory diagnostics, vaccines, antiviral susceptibility and risk assessment. Finally, and of great importance, WHO GISRS also serves as a global alert mechanism for the emergence of influenza viruses with pandemic potential.

1. Sixty-fourth World Health Assembly (2011), Resolution WHA64.5.
2. Signed SMTA2 Agreements can be accessed at www.who.int/influenza/pip/benefit_sharing/smta2_signed/en/.
Only two “codes” have been adopted so far: the “International Code of Marketing of Breast milk Substitutes”, which was adopted by the Health Assembly in 1981 to ensure protection and promotion of the safe and adequate nutrition for infants and the proper use of breast-milk substitute; and the “WHO Global Code of Practice on the International Recruitment of Health Personnel”, a comprehensive, multilateral framework for strengthening the health workforce, which places emphasis on the international mobility of health professionals and encourages information exchange on issues related to health personnel and health systems in the context of migration.

In addition, the Secretariat elaborates technical recommendations which are not approved by the Health Assembly, but rather take the form of technical documents elaborated by groups of experts or external collaborators. The Organization has established mechanisms to seek expert advice on the diverse range of health issues that it is called to handle. “Expert Committees” advise the Director-General who then reports back to the Executive Board on their meetings and recommendations and about his/her observations and recommendations. Study groups, scientific groups and collaborating centres also play a substantive role in the development of recommendations and standards.

Technical standards and recommendations may also be developed by the Secretariat based on a grant of authority by a governing body, but not endorsed or approved as such by the latter (Burci and Vignes, 2004). An example of this type is the WHO’s Model List of Essential Drugs, first prepared by a WHO Expert Committee in 1977 at the request of the Health Assembly. The Model List, which has been updated by the WHO Expert Committee on the Use of Essential Drugs every two years since 1977, serves as a guide for the development of national and institutional essential medicine lists. Another example in the area of pharmaceutical products is the International Nonproprietary Names (INNs) Programme, which aims at facilitating the identification of pharmaceutical substances or active pharmaceutical ingredients (Box 5). The list of INNs is not adopted by the governing bodies, who have however taken decisions concerning the procedure for selection of INNs and General Principles for Guidance in devising INNs.
Box 5. International Non-proprietary Names Programme (INN Programme)

The INN Programme was initiated in 1950 and began operational in 1953 when the first list of INN for pharmaceutical substances was published. The INN Programme offers a managed, co-ordinated network between WHO, INN experts and national nomenclatures committees. These three groups collaborate closely to select a single name of worldwide acceptability for each active substance that is to be marketed as a pharmaceutical. Nonproprietary names are intended for use in pharmacopoeias, labelling, product information, advertising and other promotional material, drug regulation and scientific literature, and as a basis for product names. Each INN is a unique name that is globally recognised and is public property. The names, which are given the status of an INN, are selected by WHO on the advice of members of the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations serving the INN Expert Group at the end of a very complex procedure involving the applicant, WHO Secretariat and the INN experts.

Although they have only recommendatory nature, their use is often required by national law. Since inception of the Programme, more than 8 500 INN have been established, which are used globally by National Drug Regulatory Authorities and developed in collaboration with several national drug nomenclatures bodies, such as the British Approved Names (BAN), Dénominations Communes Françaises (DCF), Japanese Adopted Names (JAN) and United States Adopted Names (USAN).

Further, the WHO Secretariat develops a wide range of guidelines, i.e. any document developed by the WHO containing recommendations for clinical practice or public health policy (WHO, 2014), intended to assist national programme managers, providers, and other stakeholders make informed decisions with respect to health care delivery. The development of such guidelines follows specific internal procedures and criteria which aim at ensuring that guidelines are free from conflict of interest, meet a public health need and are consistent with the principles of a comprehensive and objective assessment of the available evidence and of transparency. WHO also produces “rapid advice guidelines” in response to a public health emergency (for example influenza), where WHO is required to provide global leadership and guidance, while “standard guidelines” are developed in response to a request for guidance arising from uncertainty or controversy in a single clinical or policy area.

A process is in place to ensure that WHO guidelines are developed using best practices and making appropriate use of evidence. The guideline process is managed by a WHO steering group, while the formulation of
recommendations is done by the WHO Guideline Development Group (GDG) comprised of external experts and stakeholders. Guideline development plans and final products are reviewed and cleared by the WHO Guideline Review Committee to ensure that, before final clearance and publication of the guidelines, evidence is gathered, and their quality is properly assessed and synthesised. GDG membership is balanced, representative. A critical focus at all stages is to ensure that conflicts of interest are fully addressed and appropriately managed.

**Regulatory support activities**

WHO provides support to countries in the fulfilment of their responsibility to establish strong national medicines regulatory authorities. Assessment of national medicines regulatory systems, dissemination of guidance, provision of training opportunities to implement global guidelines adapted to the national context, facilitation of the exchange of regulatory information and enhancement of international regulatory collaboration among regulators, through global and regional networking, are some of the many ways through which support is provided to countries. A few examples are provided below to illustrate WHO’s supporting activities to national regulators.

The International Conference of Drug Regulatory Authorities (ICDRAs) has provided drug regulatory authorities of WHO Member States with a forum to meet and discuss ways to strengthen collaboration since 1980. As a platform established to develop international consensus, ICDRAs continues to be an important tool for WHO and drug regulatory authorities in their efforts to harmonize regulation and improve the safety, efficacy and quality of medicines. ICDRAs’ recommendations are proposed for action among agencies, WHO and related institutions.

The Paediatric Medicines Regulatory Network (PmRN), is instead composed of representatives from National Medicines Regulatory Authorities, and aims to support availability of quality medicines for children through facilitation of communication, collaboration and regulatory harmonisation across manufacturing, licensing and research.

In the area of food safety, WHO and FAO manage jointly the International Food Safety Authorities Network (INFOSAN), a global network of national food safety authorities with the secretariat in WHO. INFOSAN aims to promote the rapid exchange of information during food safety related events, share information on important food safety related issues of global interest, promote partnerships and collaboration between countries, and between networks, and help countries strengthen their capacity to manage food safety emergencies.
There are two additional areas where WHO plays a central role to support national regulatory authorities. First, WHO has the Prequalification of Medicines Programme, which aims at ensuring that medical products meet acceptable standards. While the focus was originally on medicines for treating HIV/AIDS, tuberculosis and malaria, the programme’s scope has been extended over time. Assessment of the quality, safety and efficacy of medical products is conducted by experts from WHO and national regulatory authorities worldwide based on international pharmaceutical standards. The WHO List of Prequalified Medicinal Products is used by international procurement agencies and increasingly by countries to guide the purchase of medicines. Secondly, a WHO Emergency Use Assessment and Listing (EUAL) procedure was set up to provide guidance to interested UN procurement agencies and national regulatory authorities on the quality, safety and performance of certain In Vitro Diagnostics (IVDs). An EUAL procedure may be opened with respect to any disease that has been declared a Public Health Emergency of International Concern under the IHR.

**Crisis management**

Countries face a broad range of emergencies caused by a variety of hazards, which differ in scale, complexity and international consequences. It is one of WHO’s functions to furnish necessary aid, in emergencies, upon the request or acceptance of Governments. The Organization’s role in the area of crisis management has become more operational in nature as shown, in particular, by specific surveillance and response obligations arising out of the IHR. Also, WHO intervenes on international health crisis by co-ordinating with other agencies in the context of a humanitarian crisis. WHO has the responsibility of empowering humanitarian country teams to better address the health aspects of the crisis. Indeed, it is the leading agency of the health cluster established by the Inter-Agency Standing Committee of the United Nations, which ensures inter-agency co-ordination of humanitarian assistance.

Outside the UN framework, WHO co-operates with a wide network of humanitarian partners worldwide, the Red Cross and Red Crescent movement, Collaborating Centres, universities and other academic institutions, NGOs and senior public health experts. Other key partners are intergovernmental institutions such as the African Union, the Council of Europe and the International Organization of Civil Protection.

The Organization’s work in emergencies is guided by the Emergency Response Framework. Foreign Medical Teams made up of groups of health professionals from governments, charities, militaries and international organisations have been set up to ensure the availability of health professionals to treat patients affected by emergency or disasters. They work
under the guidelines of the WHO Classification and Minimum Standards for Foreign Medical Teams that address the principles and core standards of how registered teams must function and declare their operational capabilities. The Secretariat has also developed a global registration system where emergency medical teams can be verified and classified ready to be deployed to health emergencies.

As mentioned in the first section, WHO is undergoing a substantial reform to ensure that the Organization’s emergency capacities are fit for purpose. In May 2016, the Health Assembly welcomed the progress made in the development of a new Health Emergencies Programme, the elaboration of an implementation plan and timeline for the new Programme, and the establishment of the Emergencies Oversight and Advisory Committee.32

The new Programme is designed to deliver rapid, predictable and comprehensive support to countries and communities as they prepare for, face or recover from emergencies caused by any type of hazard to human health. The new Programme has been designed to align “with the principles of a single programme, with one clear line of authority, one workforce, one budget, one set of rules and processes, and one set of standard performance metrics”. The Programme’s structure will reflect the Organization’s functions in the area of infectious hazards management, country health emergency preparedness and IHR, health emergency information and risk assessments and emergency operations (WHO, 2016c).

**Ensuring the quality of WHO instruments**

Expert advice made available to WHO at different stages of the policy-making process, significantly contributes to ensure the quality of WHO’s policies, programmes and strategies. In addition, WHO has increased efforts in assessing the implementation and impact of its activities. While *ex ante* impact assessment is only occasionally conducted, internal evaluation and monitoring of implementation by countries as well as review of normative instruments are more frequent.

**Consultation processes**

WHO engages with a wide range of stakeholder groups by providing them with an opportunity to comment on its proposed actions and, from time to time, by inviting them to participate in standard-setting activities, to sit on expert advisory groups or *ad hoc* working groups. The general public may also, on occasion, be invited to comment on proposed actions of the Organization through the WHO website.
As mentioned in the first part of this study, expert consultation is one of the essential features of WHO. Due to the manifold nature of the disciplines involved and rapid advancements affecting technical fields, the technical expertise of WHO staff is often complemented by the input of Expert Committees, as well as Study Groups, Scientific Groups and Collaborating Centres.

A good example of WHO’s interaction with a broad range of stakeholders is provided by the INN Programme. Designated members of the Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations form the so called “INN Expert Group”, to which the Secretariat transmits proposals for recommended INNs and proposals for substitution of such names. The INN Expert Group takes decisions on the selection of new INNs as a result of consultations that take place at least twice a year, and ensuing correspondence. Decisions are taken by consensus, in the lack of which the matter will continue to be discussed by correspondence or at the next consultation, if necessary. Furthermore, throughout the process that leads to the adoption or substitution of INNs, the Secretariat engages with Member States as well as national and regional pharmacopoeia commissions or other bodies designated by Member States, with the original applicant and with any interested person who may wish to file a formal objection to a proposed name within the set deadline.

Another significant example of expert consultation is provided by the Emergency Committee in the context of the IHR. The Emergency Committee provides technical advice to the Director-General in the context of a PHEIC. In addition, the IHR Review Committee makes technical recommendations to the Director-General regarding, inter alia, amendments to the IHR and provides technical advice to the Director-General with respect to standing recommendations and any other matter referred to it by the Director-General. The IHR also provide for a “consultation” process between a State Party and WHO by giving States Parties the opportunity to keep WHO informed to ensure appropriate investigative and health response measures.

As far as guidelines are concerned, a Handbook for Guidelines Development has been developed that provides detailed instructions for guideline developers on application of high quality methodology for guideline development, appropriate collection and management of experts’ declared conflict of interest, expert group composition, instructions for the management of group process, developing plans for implementing and adapting guidelines, and minimum standards for reporting. Different groups serve as platforms to allow experts, end-users, affected individuals, or other persons interested in the subject of the guidelines to participate in the guidelines development process. In addition, a separate body – the
Guidelines Review Committee – has been established to ensure specifically that WHO guidelines are of the highest quality (Box 6).

Box 6. The Guidelines Review Committee

The Guidelines Review Committee (GRC) is an advisory body composed of experts, which was established by the Director-General in 2007 to ensure that WHO guidelines are of the highest quality, and are developed through a transparent, evidence-based decision making process. The GRC meets on a monthly basis to review initial proposals for guideline development and final versions of guidelines prior to their publication.

The review of initial proposal includes an assessment of whether the guideline development process will be able to meet the WHO requirements that are described in the WHO handbook for guideline development. The review of final submissions is conducted to ensure the process and form of the recommendations has followed the WHO requirements guidelines.

The GRC also offers suggestions and advice on how to improve the quality of the guidelines. GRC is supported by a Secretariat, which inter alia co-ordinates and provides technical support on guidelines development to WHO Secretariat, organises trainings, implements the Handbook and maintains a database of GRC approved guidelines.

Evaluation and implementation monitoring

The Organization’s activities have been subject, starting from 2012, to a formal Evaluation Policy, which provides a framework for the evaluation function and evaluation processes to ensure the systematic application of a set of key principles – impartiality, independence, utility, quality and transparency. This policy applies to any assessment of an activity, project, programme, strategy, policy, theme, sector and operational area institutional performance.

The WHO Secretariat commissions three types of evaluations: thematic evaluations focussing on selected topics; programmatic evaluations focusing on a specific programme; and office-specific evaluations focusing on the work of WHO in a country, region or at headquarters in respect of WHO’s objectives and commitments. In addition, WHO develops a biennial, organisation-wide evaluation plan as part of the Organization’s planning and budgeting cycle. The Evaluation Policy, as complemented by the WHO Evaluation Practice Handbook (WHO, 2013), guides the work of the Evaluation Office, which manages, commissions or conducts corporate / centralised evaluations. Thirteen evaluations were recently conducted at all
levels of the Organization, and the implementation of their findings and recommendations analysed.

The Evaluation Office also continues to monitor progress in implementation of previous evaluations whose recommendations had not been fully responded to at the time of the annual evaluation report to the Executive Board. That being said, different solutions regarding implementation monitoring and evaluation, tailored to the specific instrument or programme concerned, have been adopted, some of which are described below.

As far as implementation by countries is concerned, it is worth recalling that, under Chapter XIV of the WHO Constitution, Member States are required to report annually to the Organization on the action taken and progress achieved in improving the health of its people, and on the action taken with respect to recommendations made to them by the Organization and with respect to conventions, agreements and regulations. This requirement has not been systematically implemented and it is difficult to identify a general trend with regard to monitoring the implementation of WHO’s recommendations. There are, however, many areas where implementation and reporting are quite robust, including the WHO FCTC, the IHR, the PIP Framework, and the WHO Global Code of Practice on the International Recruitment of Health Personnel.

**WHO Framework Convention on Tobacco Control (WHO FCTC)**

One of the most stringent mechanisms for monitoring implementation is provided by the WHO FCTC, which requires each Party to submit to the Conference of the Parties (COP), through the Convention Secretariat, periodic reports on the implementation of the Convention. The objective of reporting is to enable Parties to learn from each other’s experience in implementing the WHO FCTC and the reporting forms the basis for reviews by the COP of progress in implementation of the Convention internationally.

In November 2010, at its fourth session, the COP decided to adopt a single biennial reporting instrument consisting of a core questionnaire mandatory for all Parties. All data reported by Parties are available in an Implementation Database.

At its fifth session, the COP acknowledged the need to conduct an overall assessment on the impact of the WHO FCTC, which will be performed by a group of seven independent experts. The purpose of the assessment is to evaluate the impact of WHO FCTC on the implementation of tobacco-control measures and its effectiveness as a tool to reduce tobacco consumption and prevalence during its first decade of operation.
International Health Regulations (2005) (IHR)

Reporting requirements have also been laid down in the IHR. States Parties and the Director-General report annually to the Health Assembly on the implementation of the Regulations. The annual report submitted by the Director-General to the Health Assembly, through the Executive Board, gives an account of actions taken by the Secretariat within the framework of the Regulations regarding the international response in the previous year to public health events and emergencies, and any other relevant information regarding implementation of the IHR.

The Review Committee on the Role of International Health Regulations (2005) in the Ebola Outbreak and Response has concluded that it is imperative to prioritise the implementation of the Regulations in all countries and to strengthen the Secretariat’s capacity and partnerships to support States Parties. The Committee made 12 recommendations to ensure implementation of the Regulations based on new proposals and to improve compliance with the Regulations. With specific regard to the requirement that countries develop, strengthen and maintain core capacities for surveillance and response, WHO has developed the new IHR Monitoring and Evaluation Framework for Core Capacities. In addition to the annual reporting, the Framework includes after-action reviews, simulation exercises and addresses independent (external) evaluation. While the Secretariat’s initial focus has been on the development of the independent evaluation component, the three other components of the new tool are being finalised, together with all relevant guides and tools. Reporting to the Health Assembly using the new format is planned for 2017.

PIP Framework

In the context of the PIP Framework, implementation is subject to the oversight of the Health Assembly, and monitoring by an Advisory Group composed of eighteen independent experts in health policy, public health, or influenza from all six WHO regions, which also provides recommendations to the Director-General on its evaluation of implementation. In formulating advice to the Director-General, the Advisory Group interacts with industry and other stakeholders.

The PIP Advisory Group met in a special session in October 2015 to seek views from Member States, industry and other stakeholders on the 2016 PIP Framework Review and recommended that a small independent group of experts be established to review implementation of the PIP Framework using a transparent and inclusive approach. The Review will focus on what the achievements have been since the PIP Framework was adopted, whether implementation of the PIP Framework improved global
pandemic influenza preparedness, including interpandemic surveillance, and capacity to respond; and what the challenges and possible ways of addressing them are. It is expected that the Review Group will provide its final Report to the Director-General by October 2016, for consideration by the governing bodies of the Organization in 2017.

WHO Global Code of Practice on the International Recruitment of Health Personnel

Tools to monitor implementation are also in place with regard to the WHO Global Code of Practice on the International Recruitment of Health Personnel, mentioned above. The reporting process is indeed an integral component of the effective implementation of the voluntary principles and practices recommended by the Code. To monitor the progress made in implementing the Code, and in accordance with the request of the Health Assembly, a national self-assessment tool was created for Member States.

At the time the Secretariat presented the Sixty-sixth World Health Assembly with the first report on progress made in implementing the Code, 85 Member States had designated national authorities and 56 had submitted reports using the national reporting instrument. In 2015, the Sixty-eighth World Health Assembly reviewed the report of the Expert Advisory Group on the Relevance and Effectiveness of the Code and concluded that the Code remains relevant and that evidence of its effectiveness is emerging but work to develop, strengthen and maintain the implementation of the instrument should be viewed as a continuing process.

An updated national reporting instrument (NRI) for the second round reporting was launched in March 2015 for a period extending until February 2016. The NRI comprises three modules facilitating a comparative assessment of implementation relative to the 10 main articles of the Code, reporting on the current stock and inflow of foreign-trained doctors and nurses, and contributions by independent stakeholders to the national reporting process describing their experiences. The quantity and the quality of reporting by Member States on the implementation of the Code have improved considerably in the second round. By 4 March 2016, 74 of the 117 designated national authorities (63%) had completed and submitted a report using the NRI for the second round of national reporting. The vast majority of countries that have submitted reports in the second round are those that are the known source and destination countries for the international migration of health personnel. There has been an increase of 37% in the number of designated national authorities, which will have a significant impact on the implementation of the Code in those Member States.
Guidelines

Monitoring and evaluation systems are also used to collect and analyse data to assess the effectiveness and impact of the guideline. The WHO Handbook for Guidelines Development requires the guidelines to include outcome or performance measures that can be monitored for the main recommendations. Performance measures may be related to guideline dissemination, adaptation and endorsement in the national context, policy changes, changes in end-user knowledge and understanding, in practice performance or in health outcomes and inequities and economic or other social consequences. Ideally, there should be baseline measures against which to assess performance in relation to the potential change induced by the guideline. Operational and implementation research can be performed to assess service providers’ and end-users’ perceptions, and the values and preferences related to guideline implementation. The guideline should propose a specific set of indicators to be monitored and evaluated, including relevant disaggregation of data.

Although there has been no assessment to date of the extent to which WHO recommendations have been followed in the context of national guidelines, nor of the factors that may influence this, a recent study has concluded that uptake of WHO recommendations in national guidelines is high and associated with strength of recommendations and evidence of quality, in particular a higher level of evidence quality was associated with greater uptake at the national level irrespective of the recommendation’s strength (Nasser et al., 2015).

As far as implementation measures in WHO guidelines are concerned, though, an analysis of the implementation sections of WHO guidelines approved by the WHO GRC between December 2007 and May 2015 has shown that most mentioned implementation techniques were very brief, with general policy strategies occurring most often, and underscore the fact that stronger guidance for implementation would be welcomed, for example through structured and increased detail on implementation considerations, information on what is needed by countries to adapt the guideline to the local context and specific options from implementation strategies (Wang et al., 2016).

Codex Alimentarius

Formal tools to ensure implementation, monitoring and evaluation have not been established in the context of Codex Alimentarius. As to evaluation, in 2002 FAO and WHO decided to undertake a formal evaluation of the Codex programme. An independent evaluation team conducted more than 20 country visits and sought information from an open call for public
comment on the Codex website. The results, which found that Codex food standards were accorded very high importance by members, were mostly positive.\textsuperscript{60} The final report indicated that while Codex standards were perceived as most useful for low and middle-income countries whose domestic regulations were not yet as developed, countries at all stages of development claimed to have adopted domestically 60\% of Codex standards. Further to this report, the Fifty-sixth World Health Assembly urged Member States “to make full use of Codex standards for the protection of human health throughout the food chain”\textsuperscript{61}.

An evaluation of the functioning and results of the Codex Trust Fund after 10.5 years of its 12-years lifespan was also commissioned by the FAO/WHO Consultative Group for the Trust Fund, which concluded that the Codex Trust Fund had been successful at fulfilling its primary mandate of widening participation of developing and transition-economy countries in the Codex Alimentarius Commission and its subsidiary bodies. Its results helped to inform discussions in FAO and WHO and among Codex Member States on possible future measures to enhance further effective participation in the Codex by developing and transition-economy countries. It should be further added that the Codex Alimentarius Commission has adopted an approach for continuous monitoring of Codex work management. The Codex Commission at its Thirty-ninth session in 2016, requested the Secretariat to regularly review Codex work management as part of the monitoring of the Codex Strategic Plan and regularly inform both the Commission and the Executive Committee on the findings and recommended actions.
Assessment of the impact and success of regulatory co-operation through WHO

Benefits, costs and challenges of regulatory co-operation

WHO programmes, policies and strategies have global impacts. The fight against infectious diseases has significantly reduced the burden of such diseases, resulting in their complete eradication as in the case of smallpox, for example. WHO has also contributed since its inception to improved health outcomes through the provision of technical support to countries, the development of guidelines, norms and standards, and by facilitating the development and dissemination of drugs, vaccines and diagnostics. Public health achievements of the Organization include, amongst others, the development of the International Classification of Disease – a global standard for States to report and categorise diseases, health-related conditions and external causes of disease and injury –, mass immunisation campaigns against various diseases, and the world wide eradication of smallpox.

WHO’s role in health governance and its convening and facilitating power in defining shared problems and bringing together stakeholders to negotiate both binding and soft law instruments is of central importance. WHO also tracks health trends nationally, regionally and globally, thereby alerting the world and individual countries to emerging health threats, tracking resources and results in the interest of accountability, and demonstrating progress in reaching internationally determined goals. The adoption of the PIP Framework constitutes a positive example of the facilitating and coordinating role played by the Organization with regard to important and potentially sensitive public health issues that may benefit from an international regulatory framework. The Secretariat supported the extensive intergovernmental process that led to the adoption of the Framework and has been supporting the review process of the Framework which involves representatives of Member States, the industry and other stakeholders invited to share their views and comments on any aspect of the implementation of the Framework.
Challenges to successful regulatory co-operation within WHO may arise from the lack of human and financial resources to implement the programme of work of the Organization, difficulties in reaching consensus on specific areas of work due to differences of view among countries on underlying political and economic issues, and the lack of ratifications of legally binding agreement, which impedes the entry into force of the instrument concerned. For example, while the WHO FCTC provides an example of successful IRC through the WHO, its Protocol on Illicit Trade in Tobacco Products, adopted in November 2012, has not yet entered into force due to lack of sufficient ratifications.

Assessment of success

WHO’s history is marked by numerous examples of successful regulatory co-operation activities, which makes it challenging to give due account to all of them. Suffice it to recall, that the IHR is the only international legally binding instrument which helps the international community monitor and respond to acute public health risks that have the potential to cross borders and threaten people worldwide. WHO’s sole international convention so far, the WHO FCTC, is an evidence-based treaty that reaffirms the Preamble to the WHO Constitution, which states the right of all people to the enjoyment of the highest attainable standard of health is one of the fundamental rights of every human being and represents a milestone for the promotion of public health and provides new legal dimensions for international health co-operation. Non-legally binding instruments, such as the WHO Model List of Essential Medicines and the International Nonproprietary Names, are now used globally by almost all national health regulators.

There are at least three factors which appear necessary to ensure successful regulatory co-operation within WHO. First, the willingness among Member States to overcome diverse political interests with regard to certain specific issues surely contributes to the timely and efficient consideration of those interests by the Organization. Measures related to certain non-controversial health issues can be easily and rapidly adopted, as exemplified recently by the rapid consensus reached among countries at the Health Assembly to the need to address the global burden of mycetoma. And with political will, measures related to more complex or controversial health matters have also commanded consensus, albeit usually after extensive negotiations.

Second, solid scientific and evidence basis, as well as evidence of the impact of proposed recommendations, are vital to build Member States' confidence and willingness to take action. WHO Guidelines are developed
on the best available evidence, subject to systematic reviews. Likewise, policies for consideration by the governing bodies are informed by evidence, best practices and existing WHO technical guidance – as explicitly stated, for example, in the recently adopted WHO global plan of action to strengthen the role of the health system within a national multisectoral response to address interpersonal violence, in particular against women and girls, and against children. The technical nature of the Organization and its focus on evidence-based interventions rather than on political considerations, contributes to the consensus-building process even in areas where political and cultural sensitivities may otherwise exist.

Third, transparency and robust consultation with all member states and stakeholders in the development process of normative and technical guidance are key to engagement and effective implementation. Credible, transparent and inclusive elaboration processes of WHO policies surely contribute to successful regulatory co-operation in the field concerned.

The comprehensiveness of the Organization’s membership as well as the high rate of participation in its normative and technical instruments and activities is another factor contributes to the success of IRC within WHO. As already mentioned, WHO currently counts 194 Member States and two Associate Members, and co-operates closely with a wide range of stakeholders. Participation in WHO legally binding instruments is also very broad. The WHO FCTC currently counts 180 Parties, and the IHR are international legal instrument that is binding on 196 countries, including two non-WHO Member States. Codex Alimentarius also helps illustrate the capability of WHO, in this case in collaboration with another UN agency, to attract participation by a high number of countries. With 188 members, as well as 234 observers, the Codex Alimentarius has become the single most important international reference point for developments in food standards.

Furthermore, WHO has shown great capacity to adapt to new developments and challenges in issues of public health. Thanks to its extensive exchange of information, data collection, research and policy analysis activities, combined with the possibility of acting upon its findings through various forms of normative instruments and tools, the Organization has been able to address the increase and diversification of threats to health which have appeared since its inception. Identification of new threats is illustrated, for instance, by the recently adopted Global Plan of Action on Antimicrobial Resistance with specific work streams designed to address resistance to antimicrobial medicines that threatens human and animal health.
Finally, the capacity of the Organization to recognise in a timely manner and address the need for structural change is a critically important strength. The best recent example in this regard is the establishment of the new Emergencies Programmes in the aftermath of the Ebola Virus crisis in 2014 and 2015. The new Programme constitutes a milestone towards a more operational WHO, in addition to the technical and normative role that the Organization has traditionally played.
Conclusion

International regulatory co-operation is at the heart of WHO’s mandate. The Organization benefits from a Constitutional structure that enshrines a noble objective, empowers a global membership and provides both flexibility and accountability. As a result, it has been well placed to develop a wide range of normative, technical and, increasingly, operational mechanisms and tools to facilitate exchange of information and data among national health regulators, foster research in the field of health, and develop norms and standards through a variety of legally-binding and policy instruments. Its role in the management of health crisis faced by WHO Members is also of paramount importance, and the variety of local offices of the WHO Secretariat ensures its responsiveness to domestic conditions, both chronic and acute.

The Organization also provides several mechanisms to ensure the quality of its activities, including through regular and extensive expert consultations and engagement with stakeholders. Different tools, tailored to the specific instrument or programme concerned, have been adopted to monitor their implementation and evaluate their effectiveness. The Organization is also equipped with a general Evaluation Policy, which provides a framework for the evaluation function and processes to ensure the systematic application of a set of key principles.

Persisting problems, particularly related to the social determinants of health, as well as new and emerging public health threats make it imperative for WHO to be better equipped to address increasingly complex challenges of health in the 21st century. Since the launch of a set of reforms, in 2011, significant progress has been made towards meeting the objectives of being a more effective, efficient, transparent and accountable organisation that leverages its relative strengths and comparative advantages to improve health outcomes for all peoples. Thanks, inter alia, to the development of enhanced monitoring mechanisms, it is now possible to evaluate the impact of the various streams of reform against a set of performance indicators. While implementation of the programmatic reform is almost completed, more works remains to be done to lead the governance and managerial reforms to completion.
Furthermore, the outbreak of Ebola virus disease in West Africa drew some criticism towards the Organization’s capacity to effectively act as “the directing and co-ordinating authority on international health work” in accordance with its constitutional mandate and showed the need to reform WHO’s response in severe, large-scale emergencies. In this respect, financing the new Health Emergencies Programme is crucial to its full operationalisation. As of 22 June 2016, a significant portion of the Programme’s core budget was still not available. It is hoped that the next financing meeting planned for October-November 2016 will contribute to the mobilisation of additional voluntary contributions with a view to filling this gap. The Organization’s ability to improve implementation of the IHR by countries, as recommended by the Review Committee on the Role of the IHR in the Ebola Outbreak and Response, will be of increasing importance to respond to any future health emergency. A draft global implementation plan will be submitted to the Board, next January, to follow-up on the recommendations of the Review Committee.

Finally, the Organization faces continuous challenges in navigating areas where there may be tensions between public health considerations and political and/or economic interests. This has been evidenced, in addition to those areas mentioned above, in areas such as the Organization’s efforts to address the health impact of high sugar consumption, where guidelines developed by the Organization became subject to challenges that were seen by some to be driven by economic considerations. Addressing such challenges requires the careful marshalling of both technical processes and political will (WHO, 2015a). These, as well as other efforts, will be crucial to WHO’s continued effectiveness in fulfilling its constitutional objectives and purpose.
Notes

4. See Article 70 of the WHO Constitution. The agreements concluded with the United Nations and eleven other IGOs can be found in World Health Organization (2014), Basic Documents, 48th ed.
5. For further details, see www.who.int/hrh/com-heeg/en/ (accessed 4 October 2016)
7. Sixty-ninth World Health Assembly (2016), Resolution WHA69.10.
8. Paragraph 4 of FENSA provides as follows: “WHO’s engagement with non-State actors supports implementation of the Organization’s policies and recommendations as decided by the governing bodies, as well as the application of WHO’s technical norms and standards. Such an effective engagement with non-State actors at global, regional and country levels, also calls for due diligence and transparency measures applicable to non-State actors under this framework. In order to be able to strengthen its engagement with non-State actors for the benefit and interest of global public health, WHO needs simultaneously to strengthen its management of the associated potential risks. This requires a robust framework that enables engagement and serves also as an instrument to identify the risks, balancing them against the expected benefits, while protecting and preserving WHO’s integrity, reputation and public health mandate”.


11. Its composition, functioning and functions are addressed in Chapter V of the WHO Constitution and the Rules of Procedure adopted by the Health Assembly itself.

12. Article 18 of the WHO Constitution.


15. Workforce data as of December 2015 is available at www.who.int/about/finances-accountability/budget/wha69_hr_2015.pdf?ua=1.

16. In accordance with article 44(a) of the WHO Constitution.

17. The current Programme Budget can be accessed at www.who.int/about/finances-accountability/budget/pb201617_en.pdf (last accessed 7 June 2016).

18. Articles 34 and 55 of the WHO Constitution.

19. Article 55 of the WHO Constitution.

20. Article 18(f) and 56 of the WHO Constitution.

21. This term refers to the “base” programmes of categories 1 to 6 of the programme budget (i.e. communicable diseases, noncommunicable diseases, promoting health through the life course, health systems, preparedness, surveillance and response, and corporate services/enabling functions), plus polio, special programmes and the event-driven component of Outbreaks and crisis response. More information can be found at: http://who.int/about/finances-accountability/budget/en/ (last accessed 29 August 2016).

22. Fifty-sixth World Health Assembly (2003), Resolution WHA56.33.

23. Details of the Funding of the 2016-2017 Programme Budget can be found at http://extranet.who.int/programmebudget/biennium2016/financing.


29. A spin-off from the ICD has been elaborated by the WHO of a supplementary classification of impairments, disabilities and handicaps in 1980; and a second edition of this classification has been endorsed by the World Health Assembly under the title “International Classification of Functioning, Disability and Health”, even though the new classification is not an integral part of the ICD.

30. Under article 21 (a) of the WHO Constitution.

31. Fifty-eighth World Health Assembly (2005), Resolution WHA58.3.

32. Sixty-ninth World Health Assembly (2016), Resolution WHA69.3.

33. Sixty-ninth World Health Assembly (2016), Resolution WHA69.5.

34. Thirty-fourth World Health Assembly (1981), Resolution WHA34.22.

35. Sixty-third World Health Assembly (2010), Resolution WHA63.16.

36. They are guided by the “Regulations for Expert Advisory Panels and Committees” contained in World Health Organization (2014), Basic Documents, pp. 121-130.

37. They are guided by the “Regulations for Study and Scientific Groups, Collaborating Institutions and Other Mechanisms of Collaboration” contained in World Health Organization (2014), Basic Documents, pp. 121-130.

38. The current WHO Model List of Essential Medicines as well as the revised procedure for its update are available at www.who.int/selection_medicines/list/en/ (last accessed 11 July 2016).


42. Sixty-ninth World Health Assembly (2016), Decision WHA69(9).

43. While the Framework of Engagement with non-State Actors replaces previous policies on interaction with nongovernmental organisations and commercial enterprises, separate policies continue to apply regarding WHO’s relations with individual experts (Regulations for Expert


47. The Evaluation Policy as contained in document EB131/3 was approved by the Executive Board in decision EB131(1).

48. More information of both categories of reports can be found in document EB139/9.

49. Article 21.1 of the WHO FCTC.

50. All implementation reports and the annexes to those reports are available on the WHO FCTC web site, on country pages dedicated to each Party that has submitted at least one implementation report, www.who.int/fctc/reporting/party_reports.

51. The database can be accessed at http://apps.who.int/fctc/reporting/database.

52. Decisions FCTC/COP5(12) and FCTC/COP6(13).

53. In accordance with paragraph 1 of article 54 of the IHR and resolution WHA61.2 (2008).


55. The Sixty-ninth World Health Assembly, in May 2016, decided to request the Director-General to develop for the consideration of the Regional Committees in 2016 a draft global implementation plan for the recommendations of the Review Committee that includes immediate planning to improve delivery of the International Health Regulations (2005) by reinforcing existing approaches, and that indicates a way forward for dealing with new proposals that require further Member State technical discussions. The Director-General will submit a final version of


In February 2016, the IHR (2005) Joint External Evaluation Tool was finalised and, together with partners and experts, voluntary joint external evaluation missions to countries have begun.

The Code of Practice was adopted by the Health Assembly in resolution WHA63.16.

The report is available at www.fao.org/docrep/meeting/005/y7871e/y7871e00.htm#E10E2.

Resolution WHA56.23 Joint FAO/WHO evaluation of the work of the Codex Alimentarius Commission.

Sixty-ninth World Health Assembly (2016), Resolution WHA69.5.


Report by the Secretariat on “Reform of WHO’s work in health emergency management”. The report was prepared for consideration by the Regional Committees at their sessions in 2016 and is available at www.who.int/about/who_reform/emergency-capacities/RC_Reform-who-work-health-emergency-management-en.pdf?ua=1 (accessed 9 September 2016).

References


WHO (2016a), Decision WHA69(9) of 27 May 2016 on Reform of WHO’s work in health emergency management: WHO Health Emergencies Programme.

WHO (2016c), Reform of WHO’s work in health emergency management:
WHO Health Emergencies Programme. Report by the Director-General.

WHO (2015a), Guideline: Sugars intake for adults and children, World
Health Organization,
http://apps.who.int/iris/bitstream/10665/149782/1/9789241549028_eng.p
df?ua=1 (accessed 14 September 2016).

(accessed 14 September 2016).

WHO (2014), WHO Handbook for guideline development, 2nd edition,
World Health Organization,
http://apps.who.int/iris/bitstream/10665/75146/1/9789241548441_eng.pdf
(accessed 14 September 2016).

Organization,
http://apps.who.int/iris/bitstream/10665/96311/1/9789241548687_eng.pdf?
ua=1 (accessed 14 September 2016).

WHO (2008), International Health Regulations (2005), Second edition,
World Health Organization,
www.who.int/ihr/publications/9789241596664/en/ (accessed 14
September 2016).

Nonproprietary Names: revised procedure.

Nonproprietary Names: revised procedure. Report by the Secretariat.

WHO (2003), WHO Framework Convention on Tobacco Control, World
September 2016).

Geneva.

WHO and FAO (2016), Understanding Codex, Fourth edition,
ORGANISATION FOR ECONOMIC CO-OPERATION
AND DEVELOPMENT

The OECD is a unique forum where governments work together to address the economic, social and environmental challenges of globalisation. The OECD is also at the forefront of efforts to understand and to help governments respond to new developments and concerns, such as corporate governance, the information economy and the challenges of an ageing population. The Organisation provides a setting where governments can compare policy experiences, seek answers to common problems, identify good practice and work to co-ordinate domestic and international policies.

The OECD member countries are: Australia, Austria, Belgium, Canada, Chile, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Japan, Korea, Latvia, Luxembourg, Mexico, the Netherlands, New Zealand, Norway, Poland, Portugal, the Slovak Republic, Slovenia, Spain, Sweden, Switzerland, Turkey, the United Kingdom and the United States. The European Union takes part in the work of the OECD.

WORLD HEALTH ORGANIZATION

The WHO is the only global intergovernmental organization, and UN agency, with a specific mandate in the field of public health. By acting as the directing and co-ordinating authority on international health work, the WHO provides a unique forum to countries for exchange of information, data collection and analysis, research, and a wide spectrum of normative activities related to health. The WHO is open to all Members of the United Nations and any other State, upon approval of the Health Assembly. The WHO counts 194 Member States and two Associate Members.
International Regulatory Co-operation and International Organisations

The Case of the World Health Organization (WHO)

The World Health Organization (WHO) is the leading intergovernmental organisation in the field of health. WHO fulfils a core public policy objective by providing its Member States an institution devoted to co-operation and co-ordination, including of a regulatory nature, in the field of health. It is particularly active in providing a platform for exchange of information among regulators, pursuing data collection and analysis, putting a strong accent on the importance of research, and having an extensive range of different normative activities. WHO is also involved in crisis management in support of health emergencies faced by its Member States. WHO has undertaken extensive internal reforms to ensure its continued relevance as the United Nations public health arm, which provides a useful reference for other international organisations. This case study provides an overview of WHO’s role in International Regulatory Co-operation (IRC) – its institutional context, its main characteristics, its impacts, successes and challenges.

Contents
The context of the regulatory co-operation
Main characteristics of regulatory co-operation in the context of WHO
Assessment of the impact and success of regulatory co-operation through WHO

www.oecd.org/gov/regulatory-policy/irc.htm